Prescribing Sertraline Or Citalopram

When Pharmacogenomics Changes The Decision

Selective serotonin reuptake inhibitors (SSRIs) remain first-line treatment options for depression and anxiety disorders in UK primary care and psychiatry. Among them, sertraline and citalopram are two of the most frequently prescribed agents.

In routine practice, the choice between the two is guided by symptom profile, side-effect considerations, cardiac risk, comorbidities, and clinician familiarity. Pharmacogenomics introduces an additional layer of information that may materially influence both initial selection and dose strategy.

This article explores when genotype information may alter the prescribing decision between sertraline and citalopram, and how UK clinicians can interpret these findings in practical terms. This article is written for Doctors. If you’re a patient, you may prefer this SSRI article over on AttoPGx.com.

Understanding CYP Metabolism In Antidepressant Prescribing

Cytochrome P450 (CYP) enzymes are primarily located in the liver, with additional expression in the intestinal epithelium contributing to first-pass metabolism. These enzymes are responsible for metabolising many commonly prescribed psychotropic medications.

Genetic variation in CYP enzymes alters their functional activity, changing the rate at which a drug is metabolised. The clinical consequence is altered drug exposure — meaning higher or lower plasma concentrations at a given dose.

In SSRI prescribing, the most clinically relevant enzymes are:

• CYP2C19

• CYP2D6

Sertraline and citalopram differ in how strongly they depend on these pathways.

What Do Metaboliser Types Actually Mean?

Pharmacogenomic reports typically classify patients by phenotype:

Poor Metaboliser (PM)

• Little or no functional enzyme activity.

• Slower drug metabolism.

• Higher plasma concentrations at standard doses.

• Increased susceptibility to dose-related adverse effects.

Intermediate Metaboliser (IM)

• Reduced enzyme activity.

• Moderately increased exposure compared to normal.

Normal Metaboliser (NM)

• Expected enzyme activity.

• Standard dosing assumptions generally apply.

Rapid/Ultra Rapid Metaboliser (RM)

• Increased enzyme activity.

• Lower plasma concentrations at standard doses.

Ultrarapid Metaboliser (UM)

• Markedly increased activity.

• Potentially subtherapeutic exposure at conventional doses.

Clinically, this is not about whether a drug “works” in principle, but whether a patient is exposed to more or less of it than intended.

Pharmacology And Metabolic Differences

Citalopram

Citalopram is metabolised primarily by CYP2C19, with secondary contributions from other CYP enzymes including CYP3A4. Because CYP2C19 plays a dominant role, genetic variation in this enzyme can significantly influence drug exposure.

In CYP2C19 poor metabolisers, plasma concentrations may be substantially higher at standard doses. In ultrarapid metabolisers, concentrations may be reduced. This single-enzyme dependence makes citalopram particularly sensitive to CYP2C19 phenotype.

Sertraline

Sertraline is metabolised primarily by CYP2C19, but with secondary contributions from multiple enzymes including CYP2B6, CYP2D6 and CYP3A4.

Because metabolism is distributed across several pathways, the impact of variation in a single enzyme may be less pronounced than with citalopram. Nevertheless, CYP2C19 phenotype remains clinically relevant.

QT Prolongation And Exposure Risk

Citalopram carries established dose-dependent QT prolongation risk, reflected in MHRA guidance limiting maximum dose in certain populations.

In CYP2C19 poor metabolisers, increased exposure may amplify QT risk, particularly in patients with:

• Cardiac disease

• Concomitant QT-prolonging drugs

• Electrolyte imbalance

• Older age

In such cases, either dose adjustment or selection of an alternative SSRI such as sertraline may represent a more conservative approach.

Sertraline has one of the more favourable cardiovascular safety profiles among SSRIs and is often preferred in patients with established cardiac disease. However, altered exposure due to CYP2C19 variation can still influence tolerability.

When Genotype Meaningfully Influences Choice

Pharmacogenomic testing information may alter prescribing decisions in the following scenarios:

• Early intolerance at low doses

• Multiple SSRI failures

• Disproportionate side effects during dose escalation

• Cardiac comorbidity alongside QT concerns

• Complex polypharmacy

• Patient preference for data-guided prescribing

Importantly, pharmacogenomics predicts drug exposure rather than specific syndromes. Increased exposure may heighten susceptibility to dose-related adverse effects. Reduced exposure may contribute to apparent non-response.Genotype is one variable among many. Clinical judgement remains central.

Case Example

A 38-year-old patient discontinues citalopram within two weeks due to agitation and nausea at standard starting dose. No cardiac history.

Pharmacogenomic testing reveals CYP2C19 poor metaboliser status.

Elevated plasma exposure likely contributed to early intolerance. In this scenario, a lower starting dose or alternative SSRI selection may reduce the risk of recurrence.

Conversely, in a CYP2C19 ultrarapid metaboliser reporting limited response to standard-dose citalopram, reduced exposure may explain perceived inefficacy.

Evidence And Guideline Context

International guidance from the Clinical Pharmacogenetics Implementation Consortium (CPIC) provides genotype-informed dosing recommendations for several SSRIs, including citalopram and sertraline.

In the UK, NICE does not currently mandate routine pharmacogenomic testing prior to SSRI prescribing. Implementation therefore remains clinician-led and case-dependent.

Emerging trial data suggest genotype-informed prescribing may improve remission and response rates in selected populations, particularly where prior treatment has failed.

Frequently Asked Questions

Do CYP Enzymes Only Exist In The Liver?

CYP enzymes are predominantly expressed in the liver, which is the primary site of SSRI metabolism and systemic clearance. While some CYP activity exists in the intestinal wall and can contribute to first-pass metabolism, clinically relevant pharmacogenomic variation in SSRIs primarily reflects hepatic enzyme activity.

Does Being A Poor Metaboliser Mean The Drug Will Not Work?

No. Poor metabolisers typically have higher plasma concentrations at standard doses. The clinical issue is usually tolerability rather than lack of efficacy. Lower doses may still be effective.

Does Being An Ultrarapid Metaboliser Mean The Drug Cannot Work?

Not necessarily. It means that standard doses may produce lower-than-expected exposure. Dose optimisation within licensed limits or alternative drug selection may be appropriate.

Should All Patients Be Tested Before Starting An SSRI?

Routine pre-emptive testing is not currently mandated in UK practice. Testing may be particularly useful in patients with prior antidepressant failure, recurrent intolerance, complex polypharmacy, or significant cardiac risk.

How Do Drug–Drug Interactions Affect Interpretation?

Concomitant CYP inhibitors can reduce enzyme activity, effectively converting a normal metaboliser into a functional poor metaboliser. This phenomenon, sometimes referred to as phenoconversion, should be considered when interpreting results.

Is Citalopram More Sensitive To CYP2C19 Variation Than Sertraline?

Yes. Because citalopram relies more heavily on CYP2C19 for metabolism, genotype variation may have a more pronounced impact on exposure compared with sertraline, which utilises multiple metabolic pathways.

Conclusion

For many patients, both sertraline and citalopram are appropriate first-line options. However, CYP2C19 phenotype can materially alter drug exposure, influencing tolerability, efficacy, and cardiac risk considerations.

Pharmacogenomics does not replace clinical judgement. It provides a framework for understanding inter-individual variability in antidepressant response and may reduce trial-and-error prescribing in selected patients.

As implementation frameworks mature, genotype-informed prescribing is likely to become an increasingly relevant component of personalised mental health care in the UK.

Request a PGx Demo